DDL-1022: Nanoencapsulation of chemotherapeutic and other drugs in beta-casein micelles Ideally, all drugs could be taken orally at home, optimizing patient response to treatment, treatment costs and patient quality of life. However, the hydrophobic nature of some drugs, especially chemotherapeutic ones, has prevented us from reaching this ideal situation. In this invention beta-casein (and other casein molecules) micelles are used to encapsulate hydrophobic chemotherapeutic drugs, enabling their oral uptake. These preparations may, of course, be further coated with materials that make them gastro-intestinal tract site specific, as in targeted chemotherapy. Read more...
NUT-1051: Nano-complexes of beta-lactoglobulin and polysaccharides as vehicles for hydrophobic bioactive molecules Although foods and drinks are enriched today on a wide basis, enriching with hydrophobic content remains a problem. When enriching clear drinks the problem farther complicates since except that the method should protect and solubilize the enriching hydrophobic ingredients, the drink must also maintain its quality of transparency. In this invention compositions and methods for the formation of nanoparticles useful for carrying biologically active molecules were developed. Moreover, this invention provides a solution to clear drinks enrichment with hydrophobic biologically active molecules.
DDL-1036: Ultrasound-mediated drug delivery Presently, no vector has been approved by the FDA for in vivo gene delivery due to side effects and the death of patients in clinical trials of viral vectors. Technion researchers have developed a method for using non-viral vectors – therapeutic ultrasound waves for the delivery of genes with or without the help of additives. The uses of the invention are gene delivery for laboratory use as well as gene delivery for clinical applications to most tissues and organs. Currently a gene gun is used in some applications but only for superficial skin delivery with very low and transient transfection. The invention describes using therapeutic ultrasound waves, approved for drug delivery to the skin, for the delivery of naked DNA to most tissues and internal organs. Read more...
DDL-1160: OAK cochleates: Method and composition for a delivery platform Cochleate structures are essential in drug delivery field and may be used as adjuvants. The current invention suggests the formation of Cochleates from oligy acyl-lysine (OAK) compound. The modified OAK may have favorable properties with regard to cost of production, lack of toxicity, stability and size. Read more...
DDL-1161: Cell-derived liposomes for drug delivery A major challenge facing cancer therapy is achieving specific cytotoxic effect towards cancer cells while sparing the healthy ones. This invention describes the development of an innovative targeted system for cancer therapy based on Mesanchymal Stem Cell (MSC) derived liposomes. The engineered liposome may contain variety of anti-cancer or cytotoxin compounds which will be released directly into the cancer cells. Read more...
DDL-1279: Cell-cell fusion method with application in specific delivery of anti-nematode agents using proteins from the FF family A new fusion method developed by Technion researchers depends on the expression of a certain glycoprotein of nematode origin in the membranes of both fusion partners. The new method for biological, protein mediated, cell to cell and virus to cell fusion can be used for targeting anthelmintics in a nematode specific manner. The homotypic character of the fusion may have many applications in the medical and research fields. Read more...
DDL-1074: Compositions and methods for drug delivery The present invention is of a hydrogel containing an immobilized, naturally-occurring protein drug carrier which may be used for sustained or controlled drug delivery applications. This hydrogel matrix can also be made to be biodegradable. Following this concept, a photopolymerizable hybrid hydrogel was developed, made of poly-ethylene-glycol conjugated to PEGylated albumin for affinity based drug delivery and tissue engineering applications. Read more...
DDL-1454: A new drug and gene delivery system to the brain Though the brain has relatively high blood flow, it remains one of the least accessible organs for drug delivery due to the blood-brain barrier (BBB) and cerebrospinal fluid barrier, which separate the brain from its blood supply and control the movement of compounds in and out of the brain. Our invention consists of nano-machines composed of liposomes that deliver pharmacological compounds through the BBB to specific sub-cellular targets in the brain, allowing efficient treatment of various neurodegenerative diseases and brain damage from brain trauma. Read more...
DDL-1397: Polysaccharide-extracellular-matrix (ECM) encapsulation for cell and drug delivery Microencapsulation of cells for cell and drug delivery allows therapeutic products to be delivered to physiological targets to help restore lost function. Our invention suggests using Hydrogel-based polysaccharide-extracellular-matrix (ECM) cell capsules as a system for drug delivery. The novel system of adding ECM to the encapsulation allows regulation of relevant cell activities and secretion of drugs. Read more...
NUT-1293: Thermally-induced protein-polyphenol co–assemblies: beta lactoglobulin based nanocomplexes as protective nanovehicles for EGCG EGCG is a water-soluble polyphenol (potent antioxidant) present in green tea with numerous attributed health benefits. However, this compound is highly susceptible to oxidation, limiting drinks enrichment with EGCG. The present invention demonstrates the use of thermally modified β-lactoglobulin, forming clear solution containing nano-complexes smaller than 50nm. The nano-complexes provide good protection against polyphenol deterioration and unwanted taste Read more...
